Fig. 1

In HCC, RBBP7 is overexpressed and its overexpression is associated with poor prognosis. *, P < 0.05, **, P < 0.01, ***, P < 0.001. A. The levels of RBBP7 in various cancer types from TCGA were determined using TIMER. B. The mRNA expression levels of RBBP7 in HCC tumor samples and matched non-tumor samples (n = 15) were obtained from the GEO profile (GSE135631). C. The protein expression levels of RBBP7 in HCC tumor samples and matched non-tumor samples (n = 8) were obtained from the clinical. D. The mRNA expression levels of RBBP7 in HCC tumor samples and matched non-tumor samples (n = 8) were obtained from the clinical. E. The protein expression levels of RBBP7 in HCC tumor samples and matched non-tumor samples (n = 165) were obtained from UCLAN. F–G. Analysis of overall survival (F) and disease-free survival (G) of patients with HCC from the GEPIA2 website. H. ROC analysis predicting the sensitivity of RBBP7 in HCC based on TCGA data. I. The mRNA levels of RBBP7 in THLE-2 and tumor cells (Huh7, PLCPRF5, Li7, and Hep3B cells). J. The protein levels of RBBP7 in THLE-2 and tumor cells (Huh7, PLCPRF5, Li7, and Hep3B cells)